Federal regulators have warned the maker of Ozempic and Wegovy that it failed to report possible drug side effects to the government.

GLP-1 receptor agonist therapy for type 2 diabetes or obesity is associated with a significantly lower risk of developing ...

GLP-1RAs are associated with greater annualized total hip bone loss in patients without diabetes, driven primarily by weight ...

The guidelines prioritize earlier lifestyle interventions for the prevention of atherosclerotic cardiovascular disease.

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

In patients with diabetes and multivessel CAD, ticagrelor fails to meet noninferiority criteria compared with prasugrel at ...

The new guidance includes recommendations for MRI and transvaginal ultrasonography in the evaluation of suspected ...

Topline data were announced from a phase 3 trial evaluating DTX301 (avalotcagene ontaparvovec) for the treatment of OTC deficiency.

A predictive nomogram incorporating 16 clinical and biochemical variables demonstrated high diagnostic performance, with a sensitivity of 0.88 and a specificity of 0.92 for identifying uterine ...

Deaths linked to pregnancy and childbirth fell slightly in the United States in 2024, according to a new study.

Test your knowledge on the top endocrinology research findings from February 2026. In February, the research realm yielded an abundance of clinical findings that can shift your endocrine practice. The ...

Desmoda (desmopressin acetate) Vasopressin 2 receptor agonist Management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. FDA Approves Desmoda Oral ...